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Abstract Activated neutrophils secrete two forms of IL-8 with 77 and 72 amino acids, IL-8(77) and IL-8(72), along with proteinases that could 
process these cytokines. Significant conversion of IL-8(77) to more potent, N-terminally truncated forms was observed upon incubation with 
neutrophil granule lysates and purified proteinase-3. IL-8(72) was considerably more resistant o proteolytic processing than IL-8(77). The present 
observations indicate that neutrophil proteinases released in inflamed tissues convert IL-8 to more active forms and therefore tend to conserve or 
enhance, rather than decrease IL-8 activity. 
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1. Introduction 
Interleukin-8 (IL-g) belongs to a family of small chemotactic 
cytokines, now called chemokines, which are released by 
phagocytes and a variety of tissue cells upon challenge with 
inflammatory stimuli [1,2]. IL-8 and several analogs, NAP-2 [3], 
GROa, GROj? and GROy [4], and ENA- [5], activate neutro- 
phi1 leukocytes via common heptahelical receptors coupled to 
GTP-binding proteins, and induce three main responses: shape 
change and migration, exocytosis of enzymes and other storage 
proteins, and the respiratory burst [2]. IL-8 is generated as a 
precursor of 99 amino acids, and is secreted after cleavage of 
a signal peptide of 20 residues. The mature protein is processed 
at the N-terminus by extracellular proteinases yielding several 
biologically active forms the most abundant of which consist 
of 77 and 72 amino acids [2]. Neutrophils were shown to release 
IL-8 during phagocytosis [6] and after stimulation, e.g. with 
fMLP [7], or LPS [6,8], but the role of neutrophil proteinases 
in IL-8 processing is unknown. 
Activated neutrophils release a variety of proteinases with 
broad substrate specificity that can process chemokines and 
modify their biological activity. We have determined the forms 
of IL-8 released by neutrophils, and have studied the processing 
of IL-8 and its analogs, NAP-2 and GROa, by neutrophil 
proteinases. Our results show that the proteinases tend to en- 
hance IL-8 activity by conversion into derivatives that are more 
potent and more resistant to proteolysis. 
2. Materials and methods 
2.1. Materials 
IL-8(72) and IL-8(77), NAP-2 and GROa were prepared by stepwise 
chemical synthesis by Dr. Ian Clark-Lewis (University of British 
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Columbia, Vancouver, Canada) [9]. Bovine pancreatic trypsin and chy- 
motrypsin (Boehringer Mannheim) were active-site titrated using 
p-nitrophenyl-p’-guanidinobenzoate [lo] and 4-nitrophenylacetate [l 11, 
respectively. Active-site titrated human leukocyte lastase, cathepsin G 
and al-proteinase inhibitor were provided by Dr. J. Bieth (INSERM 
U.237, Strasbourg, France), and purified proteinase-3 [12,13] by Dr. B. 
Gray (University of Minnesota, Minneapolis, MN, USA). Bovine neck 
ligament elastin, bovine plasma fibrinogen and bovine achilles tendon 
collagen I were purchased from Sigma. 
2.2. Purification of IL-S from supernatant of stimulated neutrophils 
Neutrophils were suspended in 1000 ml MEM supplemented with 2% 
(v/v) plasma protein solution (Central Laboratory of the Swiss Red 
Cross) at 5 x 10’ cells/ml, and stimulated with 1 &ml lipopolysac- 
charide for 18 h at 37”C/5% CO*. The medium was diluted with an 
equal volume of buffer (20 mM potassium phosphate buffer, pH 7.2, 
containing 20 mM NaCl, 1 mM EDTA and 5% glycerol), and loaded 
onto a 13-ml phosphocellulose column (Whatman Pl l), and elution 
was performed with 120 ml of a linear NaCl gradient (0.02 to 2 M). 
Fractions with IL-8 activity were pooled and further purified by re- 
versed-phase HPLC on a C4 column (10 x 100 mm, 20 pm, Aquapore, 
Applied Biosystems) which was eluted at 2 ml/min with a gradient of 
0 to 80% acetonitrile in 0.1% trifluoroacetic acid (TFA). IL-8 activity 
was rechromatographed on a microbore C4 column (2.1 x 100 mm, 
7 pm, Aquapore, Brownlee Labs) which was eluted at 0.5 ml/min with 
a gradient of 0 to 75% acetonitrile in 0.1% TFA at an increment of 
1.25% per min. Active fractions were rerun on a CN-propyl column 
(2.0 x 100 mm, 7 pm, Nucleosil 300-7 pm, Macherey-Nagel) as de- 
scribed for the C4 column. 
2.3. Reduction of IL-8(72) 
20 pg IL-8(72) were treated with 7 M guanidine and 10 mM dithio- 
threitol in 2 ml 0.3 M Tris/HCl, pH 8.5, and then alkylated for 2 h at 
room temperature with 22 mM iodoacetamide. The preparation was 
dialyzed overnight against 50 mM Tris/HCl, pH 8.3. Reduced IL-8(72) 
was devoid of biological activity. 
2.4. Neutrophil granule lysate 
Human neutrophils were isolated from buffy coats of donor blood 
(Central Laboratory of the Swiss Red Cross) [14]. The cells (108/ml) 
were suspended in PBS, pH 7.4 and disrupted by nitrogen cavitation 
(20 min, 30 bar). The homogenate was centrifuged at 250 x g for 10 min 
at 4”C, and a granule pellet was obtained by centrifugation of the 
supematant at 100,000 x g for 30 min. Granule enzymes were extracted 
by resuspending the pellet in 0.2 M glycine, pH 3.0, containing 0.2% 
Triton X-100. The lysate was stored at -20°C in portions correspond- 
ing to 2 x 10’ cells. The lysate from 5 x lo6 neutrophils contained 15 pg 
elastase, as estimated by comparison with purified, active-site titrated 
neutrophil elastase using N-methoxysuccinyl-Ala-Ala-Pro-Val-p- 
nitroanilide as substrate, 3 fig vitamin B,,-binding protein estimated by 
the binding of cyano-[“Colcobalamin, and/?-glucuronidase ata specific 
activity of 5 nmol/min/mg [15,16]. 
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2.5. Proteolytic degradation 
Mixtures containing granule lysate or a purified proteinase, achem- 
okine as substrate and additions as indicated, were incubated in PBS 
for 0.5 to 24 h at 37°C. The reaction was stopped by freezing at -70°C 
for later assays of biological activity, separation by HPLC, or SDS- 
PAGE analysis. 
2.6. Fragment analysis 
Proteolytic fragments were seperated by SDS-PAGE (18% 
polyacrylamide containing 7.2 M urea) under reducing conditions (2% 
B-mercaptoethanol), and visualized by silver staining. For sequence 
analysis, proteins were separated by HPLC on a Brownlee Aquapore 
Butyl-column (2.1 mm x 10 cm) using a gradient of 60% acetonitrile. 
NH,-terminal sequencing was performed by automated Edman degra- 
dation with a gas-phase sequencer (Model 477A, Applied Biosystems, 
Inc.). 
2.7. Bioassa_vs 
The biological activity of chemokines was assessed in human eutro- 
phils by determining enzyme release [14,16] or H,O* formation during 
the respiratory burst [17]. 
3. Results 
3.1. Neutrophil IL-8 
A major peak of biologically active IL-8 was obtained by 
reversed-phase HPLC from the supernatants of LPS-stimu- 
lated neutrophils. Two forms were identified in this peak by 
N-terminal sequencing: About 60% of the total activity corre- 
sponded to IL-8(77) and 40% to IL-8(72). IL-8(77) is the pre- 
dominant form found in cultures of fibroblasts, endothelial 
cells and synovial cells [ 18-2 11, while human monocytes largely 
process IL-8 to the IL-8(72) form [22,23] which is considerably 
more active [24]. 
3.2. Processing of IL-8( 77) by granule enzymes 
It was of interest to study possible modifications of IL-8(77), 
the predominant form synthesized in neutrophils, by a lysate 
of neutrophil granules, which contains serine-, thiol-, carboxy- 
and metallo-proteinases [12], and corresponds to the mixture 
of proteolytic activities that are liberated at sites of inflamma- 
tion. As shown by SDS-PAGE, a cleavage product of IL-8(77) 
was obtained which comigrated with IL-8(72) (Fig. la). The 
conversion of IL-8(77) (AVLPRSAKELRC...) to IL-8(72) 
(SAKELRC...) was confirmed by sequence analysis. It resulted 
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in a progressive increase in respiratory burst activity over 5 h 
(Fig. lb). No intermediate sequence or further truncations were 
found after incubation for 5 h. The processing of IL-8(77) was 
prevented by diisopropyl fluorophosphate or al-proteinase in- 
hibitor suggesting that a serine proteinase was involved. EDTA 
and leupeptin, which block metallo- and thiol-proteinases, re- 
spectively, had no effect. 
3.3. Processing of IL-8(77) by purljied proteinases 
The effect of single neutrophil serine proteinases was also 
studied. No change in respiratory burst activity was observed 
after exposure of IL-8(77) to elastase or cathepsin G, but a 
marked increase was obtained with proteinase-3. This process 
was relatively slow, with a maximum increase of activity after 
5 h (Fig. 2). Edman degradation analysis yielded the N-terminal 
sequence KELRC... indicating that proteinase-3 generates IL- 
8(70), the potent 70 amino acid form of IL-8. About 20% of 
IL-8(77) was converted to IL-8(70) in 5 h. 
3.4. Processing of IL-8( 72) 
IL-8(72) was also exposed to a neutrophil granule lysate and 
purified proteinases, and changes in size and biological activity 
were monitored. Incubations of IL-8(72) with the granule lysate 
at pH values between 4 and 8 for up to 24 h, did not lead to 
the formation of cleavage products that could be assessed by 
SDS-PAGE. The biological activity of IL-8(72) decreased only 
slightly, i.e. on average by 7% after 5 h and 25% after 24 h (not 
shown). IL-8(72) was also incubated at neutral pH with samples 
of granule lysate that had been treated with aminophenylmer- 
curie acetate to fully activate the metalloproteinases [25], but 
no changes in biological activity were observed, although the 
enzyme preparation readily degraded N-methoxysuccinyl-Ala- 
Ala-Pro-Val-p-nitroanilide (11.4 pmol/min/pg granule lysate) 
and azocoll (3.2 mg/min/pg granule lysate). 
No cleavage products were apparent on SDS-PAGE, after 
incubation of IL-8(72) with human neutrophil elastase or 
cathepsin G, while degradation into smaller peptides was ob- 
served in the presence of trypsin or chymotrypsin (Fig. 3a). 
Despite the absence of detectable degradation products, elas- 
tase and cathepsin G led to a relatively slow, gradual loss of 
biological activity (Fig. 3b). By contrast, proteolytic degrada- 
b seconds 
Fig. 1. Conversion of IL-8(77) to IL-8(72). 2 PM IL-8(77) was incubated with granule lysate (60 pg protein) in 1 ml PBS. (a) SDS-PAGE of samples 
withdrawn at time 0 (lane 2), and after 10 min (lane 3), 30 min (lane 4), 2 h (lane 5), 8 h (lane 6) and 24 h (lane 7). Lane 1, aprotinin (6.5 kDa) and 
lysozyme (14.4 kDa); lane 8, IL-8(72) standard. (b) Respiratory burst activity obtained with 10 ~1 samples withdrawn after 0.5, 2, 5 and 8 h (right 
panel), and of 10 ~1 2 PM IL-8(72) and IL-8(77) (top and bottom, left panel). Separate xperiments howed that granule lysate does not influence 
the respiratory burst response of neutrophils to IL-8(72) or IL-8(77). Similar results were obtained in four additional experiments. 
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Fig. 2. Conversion of IL-8(77) to IL-8(70) by proteinase-3.2pM IL- 8(77) was incubated with 50 nM purified proteinase-3 in 1 ml PBS. (a) Respiratory 
burst activity obtained with 10 ~1 samples withdrawn after 0, 2, 5, 9 and 24 h. (b) Elastase release induced in neutrophils by 1 ~1 samples withdrawn 
after 2, 5 and 9 h. Control experiments were performed with 1 ~1 samples of 2 PM solutions of IL-8(77) (77), IL-8(72) (72) and IL-8(70) (70). 
tion was very rapid and complete after denaturation of IL-8(72) 
by reduction and alkylation of the disulfide bonds. This result 
indicates that the tertiary structure confers to native IL-8(72) 
its marked resistance to proteolysis. 
The proteolytic inactivation of IL-8(72) and the two related 
chemokines, NAP-2 and GROa, was then compared. The bio- 
logical activity of all three chemokines decreased as a first- 
order function of time of incubation. As shown by the half-life 
values, IL-8(72) was more susceptible than NAP-2 and GROa 
to elastase and cathepsin G, but more resistant to trypsin and 
proteinase-3 (Table 1). NAP-2 was degraded rapidly by pro- 
teinase-3 and trypsin, but was not affected by chymotrypsin. 
3.5. Competing substrates and inhibitors 
To gain more information about the efficiency of chemokine 
degradation in inflamed tissues, the inactivation of IL-8(72) 
was assessed in the presence of natural substrates as well as 
al-proteinase inhibitor, which abound in the extracellular 
space. As shown in Fig. 4, inactivation of IL-8(72) by elastase 
and cathepsin G was prevented by fibrinogen and was retarded 
considerably by elastin. By contrast type-1 collagen, which has 
only low affinity for elastase and is not a substrate of cathepsin 
G, inhibited the degradation of IL-8(72) by elastase only 
slightly, and did not influence degradation by cathepsin G. 
Table 1 
Interaction of proteinases with IL-8, NAP-2 and GROa* 
Expectedly, the effect of elastase, cathepsin G, trypsin and 
chymotrypsin was prevented by al-proteinase inhibitor which 
is known irreversibly to block serine proteinases (not shown). 
4. Discussion 
Proteinases present in neutrophil granule lysates were found 
to convert IL-8(77) into IL-8(72) resulting in enhanced biolog- 
ical activity. N-terminal processing of IL-8(77) was also ob- 
served with proteinase-3 which, however, generated IL-8(70), 
a form that is about IO-fold more potent [24]. The conversion 
of the 77 into the 70 amino acid form of IL-8 implies the 
cleavage of an Ala-Lys bond, which is in agreement with the 
results of a former study showing that proteinase-3 acts prefer- 
entially on bonds that link small aliphatic amino acids to other 
residues [26]. Although elastase shares with proteinase-3 a sub- 
stantial degree of active site homology and a similar substrate 
specificity [26], it did not convert IL-8(77) to more potent deriv- 
atives. The conversion of IL-8(77) to IL-8(70) was not observed 
with neutrophil granule lysates, and no IL-8(70) was found in 
supematants of neutrophils stimulated with LPS. This suggests 
that proteinase-3 may not be present in sufficient amounts in 
the lysate or may be inactivated by other enzymes or inhibitors. 
The neutrophil granule enzymes lastase, cathepsin G and 
Cathepsin G Elastase Chymotrypsin Trypsin Proteinase-3 
k 612 k 
(h-7 
tm k t,/z k t1/2 
@I (h-7 
tm 
(h) (0 (h) (h-‘) @) :h-I) (h) 
IL-8 0.306 2.26 0.174 3.98 0.076 9.34 0.067 10.35 0.040 17.03 
NAP-2 0.083 8.24 0.101 6.94 _** 2.650 0.26 2.650 0.22 
GRO-a 0.029 24.40 0.086 7.94 0.104 6.67 0.418 1.66 0.310 2.26 
*Apparent first order inactivation rate constants (k) and half times of inactivation (t,,2 = 0.693/k) of IL-8, NAP-2 and GROa by proteinases. 50 nM 
enzyme was incubated with 200 nM substrate in 1 ml PBS. Samples of 100 ~1 were withdrawn at times between 0 and 24 h at 37°C and activity 
was assessed as release of elastase or N-acetyl;B-glucosaminidase. 
**NAP-2 is not affected by chymotrypsin. 
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Fig. 3. Effect of proteinases on IL-8(72). 5 PM IL-8(72) was incubated with 50 nM of the purified enzymes in 0.1 ml PBS. (a) SDS-PAGE analysis 
of 50 ~1 samples withdrawn at time 0 (lane 2), 5 h (lanes 3, 5, 7, 9, 11) or 24 h (lanes 4, 6, 8, 10). The enzymes were: elastase (lanes 3, 4), cathepsin 
G (lanes 5,6), chymotrypsin (lanes 7, 8) and trypsin (lanes 9, 10). Lane 11, reduced IL-8(72) incubated with 50 nm elastase; lane 12, reduced IL-8(72) 
without proteinase. Lane 1, aprotinin (6.5 kDa) and lysozyme (14.4 kDa). (b) Respiratory burst activity obtained with 10~1 samples withdrawn after 
5 h (left) or 24 h (right) incubation with PBS, trypsin, chymotrypsin, elastase or cathepsin G (top to bottom). Similar results were obtained in two 
additional experiments. 
proteinase-3 also inactivated NAP-2 and GROa. Inactivation 
by granule lysates was markedly slower than that observed with 
pure proteinases, suggesting that enzymes and other proteins 
present in the lysate may act as competing substrates. 
The relatively rapid processing of IL-8(77) and relatively 
slow inactivation of IL-8(72) suggest that the enzymes released 
in inflamed tissues by activated neutrophils tend to enhance, 
rather than decrease the activity of IL-8 and possibly other 
chemokines. In addition to tissue cells and mononuclear 
phagocytes, stimulated neutrophils themselves have the capac- 
ity to produce IL-8 and thus to reinforce their own recruitment 
[6,7]. The conversion of IL-8(77) to IL-8(72) and/or IL-8(70) 
will amplify chemotactic activity, and further enhance the proc- 
ess of neutrophil recruitment. 
The three-dimensional structure of IL-8 comprises a short, 
conformationally disordered N-terminus followed by three an- 
a 
I 
tiparallel B-strands leading, via a /I-turn, to a C-terminal a-helix - 120- b 
[27,28]. Several putative cleavage sites for elastase, cathepsin G 
and proteinase3 are present in the region of the B-strands, 
between the second and fourth cysteine (Fig. 5) They are un- 
likely to be accessible to proteolytic attack in the folded mole- 
5 go- 
CC 
cule, but become exposed when IL-8 unfolds, explaining the 
rapid degradation observed upon reduction of the disulfide 
bonds. 
The N-terminal region is less protected than other parts of 
60 - 
the IL-8 molecule, and this could explain the relatively efficient 
conversion of IL-8(77) to IL-8(72) and IL-8(70) by neutrophil 
proteinases. It has been shown that the sequence Glu-Leu-Arg 
preceding the first cysteine is essential for IL-8 receptor binding 
and biological activity [24,29]. It is interesting to note that 
neutrophil proteinases readily process the extended N-terminus 
of IL-8(77), but are much less active on IL-8(72), and are 
apparently unable to cleave the receptor-binding Glu-Leu-Arg 
domain. This region must be sterically protected since the Leu- 
Arg bond, a putative cleavage site of cathepsin G, remains 
intact. The N-terminal domain of other chemokines related to 
IL-8 also appears to be particularly susceptible to proteolytic 
attack. In a former study, we showed that connective tissue- 
activating peptide III is readily converted to neutrophil-activat- 
ing proteins (NAP-2 and variants) by N-terminal processing 
through serine proteinases from neutrophils and monocytes 
30 - 
b, 
00 
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Fig. 4. Effect of added proteinase substrates on IL-8(72) degradation. 
50 nM elastase (a) or cathepsin G (b) were incubated with 8 mg pro- 
teinase substrate and 200 nM IL-8(72) in 1 ml PBS. Exocytosis of 
N-acetyl;B-glucosaminidase (a)or elastase (b) induced in neutrophils 
by 1 ~1 samples withdrawn at the times indicated. The proteinase sub- 
strates were: Fibrinogen (m), elastin (+), type-1 collagen (A). Control 
incubations were performed in the absence of additional substrate (0). 
Separate xperiments howed that fibrinogen, elastin and type-1 colla- 
gen did not influence the response of neutrophils to IL-8(72). Similar 
results were obtained in four additional experiments. 
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Fig. 5. Structure of IL-8(77). Amino acid sequence and putative cleav- 
age sites for elastase, cathepsin G, proteinase-3 and neutrophil granule 
enzymes. 
[30]. Furthermore, it was recently shown that IL-8(77) is con- 
verted to IL-8(72) by thrombin [21] and plasmin [31]. 
The present study was not designed to assess the proteolytic 
degradation of the C-terminal helix. It is known, however, that 
the a-helix can be shortened by two turns without loss of activ- 
ity and that IL-8 remains biologically active even upon elimina- 
tion of the complete C-terminal sequence following the last 
cysteine [24]. 
Two properties qualify IL-8 as particularly suited as a medi- 
ator of inflammation, its production by cells of inflamed tissues 
and by immigrant leukocytes, and its local persistence in active 
form. In this respect, IL-8 and related chemokines differ radi- 
cally from other chemotactic agonists, like C5a, fMet-Leu-Phe, 
LTB, and PAF, which are rapidly inactivated by oxidation or 
hydrolysis. The present evidence for the low effectiveness of 
neutrophil proteinases in the inactivation of IL-8, and for their 
potential role in the formation of biologically more potent 
forms by N-terminal processing, uncovers a mechanism for 
conserving IL-8 dependent chemotactic activity at sites of in- 
flammation. 
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